Published in ACS Chem Neurosci on March 24, 2015
Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease. ACS Med Chem Lett (2015) 0.77
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
The neurobiology of zinc in health and disease. Nat Rev Neurosci (2005) 5.07
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 4.42
Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci (1998) 4.19
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Untangling amyloid-β, tau, and metals in Alzheimer's disease. ACS Chem Biol (2013) 1.82
Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics (2008) 1.58
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res (2000) 1.42
Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics. Nat Commun (2014) 1.37
Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis (2008) 1.31
Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci Ther (2010) 1.19
Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci (1999) 1.12
Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Aging Cell (2006) 1.01
The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging (2004) 0.98
The role of zinc in Alzheimer's disease. Int J Alzheimers Dis (2010) 0.94
Imaging biomarkers associated with cognitive decline: a review. Biol Psychiatry (2014) 0.94
Therapeutic redistribution of metal ions to treat Alzheimer's disease. Acc Chem Res (2012) 0.92
Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis (2013) 0.90
Rapid microfluidic flow hydrogenation for reduction or deprotection of 18F-labeled compounds. Chem Commun (Camb) (2013) 0.88
Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. J Labelled Comp Radiopharm (2013) 0.83
PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev (2014) 0.82
Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques. J Am Chem Soc (2013) 0.82
Targeting Metal-Aβ Aggregates with Bifunctional Radioligand [(11)C]L2-b and a Fluorine-18 Analogue [(18)F]FL2-b. ACS Med Chem Lett (2014) 0.81
A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques. Chem Commun (Camb) (2010) 0.78
Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med (2009) 10.31
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med (2012) 7.85
Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). Trials (2011) 1.57
The emerging chondrocyte channelome. Front Physiol (2010) 1.08
Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int (2010) 1.04
Characterization of a stretch-activated potassium channel in chondrocytes. J Cell Physiol (2010) 0.95
Interactions between oligodendrocyte precursors control the onset of CNS myelination. Dev Biol (2010) 0.94
Rapid microfluidic flow hydrogenation for reduction or deprotection of 18F-labeled compounds. Chem Commun (Camb) (2013) 0.88
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys (2013) 0.87
Project Grow-2-Gether: a study of the genetic and environmental influences on child eating and obesity. Twin Res (2002) 0.84
A nutrient-sensitive restriction point is active during retinal progenitor cell differentiation. Development (2014) 0.83
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. Hum Pathol (2012) 0.82
Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer Activity. J Med Chem (2015) 0.82
Creating asthma-friendly schools: a public health approach. J Sch Health (2006) 0.82
Potassium channels in articular chondrocytes. Channels (Austin) (2012) 0.81
ACR MRI accreditation: yesterday, today, and tomorrow. J Am Coll Radiol (2005) 0.79
Discovery of a Potent Anti-tumor Agent through Regioselective Mono-N-acylation of 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine. Medchemcomm (2013) 0.78
Peak oil, urban form, and public health: exploring the connections. Am J Public Health (2011) 0.77
Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors. Curr Top Med Chem (2016) 0.75
Re: Marco Roscigno, Maurizio Brausi, Axel Heidenreich, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011;60:776-83. Eur Urol (2011) 0.75
Multidisciplinary urological engagement in translational renal cancer research. BJU Int (2014) 0.75
What's Your Position? Strategies for Safely Reaching Patient Comfort Goals After Cardiac Catheterization via Femoral Approach. Dimens Crit Care Nurs (2017) 0.75
Creating environment for cancer care. Health Facil Manage (2008) 0.75